| 3252- | PBG, | Propolis Extract and Its Bioactive Compounds—From Traditional to Modern Extraction Technologies |
| - | Review, | NA, | NA |
| 3253- | PBG, | Brazilian red propolis extract enhances expression of antioxidant enzyme genes in vitro and in vivo |
| - | in-vitro, | Nor, | HEK293 | - | in-vivo, | Nor, | NA |
| 3259- | PBG, | Propolis and its therapeutic effects on renal diseases: A review |
| - | Review, | Nor, | NA |
| 3257- | PBG, | The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review |
| - | Review, | Var, | NA |
| 3256- | PBG, | Mechanisms of Apoptosis and Cell Cycle Arrest Induced by Propolis in Cancer Therapy |
| - | Review, | Var, | NA |
| - | in-vitro, | Pca, | DU145 |
| 4946- | PEITC, | Phenethyl Isothiocyanate Inhibits Oxidative Phosphorylation to Trigger Reactive Oxygen Species-mediated Death of Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 4947- | PEITC, | Phenethyl Isothiocyanate (PEITC) Inhibits the Growth of Human Oral Squamous Carcinoma HSC-3 Cells through G0/G1 Phase Arrest and Mitochondria-Mediated Apoptotic Cell Death |
| - | in-vitro, | Oral, | HSC3 |
| 4948- | PEITC, | Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo |
| - | vitro+vivo, | Oral, | CAL27 | - | vitro+vivo, | Oral, | FaDu | - | vitro+vivo, | Oral, | SCC4 | - | vitro+vivo, | Oral, | SCC9 |
| 4949- | PEITC, | Phenethyl Isothiocyanate Exposure Promotes Oxidative Stress and Suppresses Sp1 Transcription Factor in Cancer Stem Cells |
| - | in-vitro, | Cerv, | HeLa |
| 4950- | PEITC, | Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential |
| - | vitro+vivo, | Pca, | PC3 |
| 4951- | PEITC, | ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis |
| - | in-vitro, | Ovarian, | PA1 | - | in-vitro, | Ovarian, | SKOV3 |
| 4952- | PEITC, | Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model |
| - | in-vitro, | CRC, | HCT116 |
| 4953- | PEITC, | PEITC: a natural compound effective in killing primary leukemia cells and overcoming drug resistance |
| - | in-vitro, | CLL, | NA |
| 4954- | PEITC, | Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 4955- | PEITC, | Phenethyl isothiocyanate-induced cytoskeletal changes and cell death in lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 4956- | PEITC, | Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells |
| - | vitro+vivo, | Lung, | A549 |
| 4957- | PEITC, | Phenethyl Isothiocyanate (PEITC) from Cruciferous Vegetables Targets Human Cancer Stem-Like Cells |
| - | vitro+vivo, | Cerv, | HeLa |
| 4958- | PEITC, | Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model |
| - | vitro+vivo, | CRC, | NA |
| 4959- | PEITC, | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment |
| - | in-vitro, | Ovarian, | NA |
| 4960- | PEITC, | Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells |
| - | in-vivo, | Cerv, | HeLa |
| 4961- | PEITC, | Phenethyl isothiocyanate suppresses cancer stem cell properties in vitro and in a xenograft model |
| - | vitro+vivo, | CRC, | HCT116 |
| 4962- | PEITC, | Ba, | PSO, | Targeting Breast Cancer Stem Cells |
| - | Review, | BC, | NA |
| 4963- | PEITC, | Sensory Acceptable Equivalent Doses of β - Phenylethyl isothiocyanate (PEITC) Induce Cell Cycle Arrest and Retard Growth of p53 Mutated Oral Cancer In Vitro and In Vivo |
| - | vitro+vivo, | Oral, | CAL27 | - | vitro+vivo, | Oral, | FaDu | - | vitro+vivo, | Oral, | SCC4 | - | vitro+vivo, | Oral, | SCC9 |
| 4964- | PEITC, | Irreversible Inhibition of Glutathione S-Transferase by Phenethyl Isothiocyanate (PEITC), a Dietary Cancer Chemopreventive Phytochemical |
| - | in-vitro, | Var, | NA |
| 4935- | PEITC, | Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo |
| - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | PC3 |
| 4930- | PEITC, | Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy |
| - | vitro+vivo, | Lung, | A549 |
| 4921- | PEITC, | The Potential Use of Phenethyl Isothiocyanate for Cancer Prevention |
| - | Review, | Var, | NA |
| 4922- | PEITC, | Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms |
| - | Review, | Var, | NA |
| 4923- | PEITC, | Quantitative chemical proteomics reveals that phenethyl isothiocyanate covalently targets BID to promote apoptosis |
| - | Study, | Var, | NA |
| - | Trial, | Oral, | NA |
| 4920- | PEITC, | Cisplatin, | PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p |
| - | vitro+vivo, | NSCLC, | A549 |
| 4919- | PEITC, | Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73 |
| - | in-vitro, | Var, | NA |
| 4918- | PEITC, | Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights |
| - | Review, | Var, | NA |
| 5014- | PEITC, | Xan, | Combination of xanthohumol and phenethyl isothiocyanate inhibits NF-κB and activates Nrf2 in pancreatic cancer cells |
| - | in-vitro, | PC, | NA |
| 4944- | PEITC, | Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral cancer cells with varying p53 mutations |
| - | in-vitro, | Oral, | NA |
| 4925- | PEITC, | PEITC triggers multiple forms of cell death by GSH-iron-ROS regulation in K7M2 murine osteosarcoma cells |
| - | in-vitro, | OS, | NA |
| 4926- | PEITC, | PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT |
| - | in-vitro, | CRC, | SW48 |
| 4927- | PEITC, | Targeting ferroptosis in osteosarcoma |
| - | Review, | OS, | NA |
| 4928- | PEITC, | Dietary phytochemical PEITC restricts tumor development via modulation of epigenetic writers and erasers |
| - | vitro+vivo, | Colon, | SW-620 |
| 4929- | PEITC, | PacT, | Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4931- | PEITC, | Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA-194 |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 4932- | PEITC, | Pharmacokinetics and Pharmacodynamics of Phenethyl Isothiocyanate: Implications in Breast Cancer Prevention |
| - | Review, | BC, | NA |
| 4933- | PEITC, | Phenethyl isothiocyanate inhibits metastasis potential of non-small cell lung cancer cells through FTO mediated TLE1 m6A modification |
| - | vitro+vivo, | Lung, | H1299 | - | vitro+vivo, | SCC, | H226 |
| 4934- | PEITC, | Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5016- | PEITC, | Phenethyl Isothiocyanate (PEITC) interaction with Keap1 activates the Nrf2 pathway and inhibits lipid accumulation in adipocytes |
| - | in-vitro, | Nor, | NA |
| 4936- | PEITC, | PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth |
| - | in-vivo, | BC, | MDA-MB-231 |
| 4937- | PEITC, | PEITC: Functional Compound for Primary and Tertiary Chemoprevention of Cancer |
| 4938- | PEITC, | Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers |
| - | Trial, | Nor, | NA |
| 4939- | PEITC, | Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo |
| - | in-vitro, | Pca, | PC3 | - | ex-vivo, | Nor, | HUVECs |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid